PMOD Technologies' vendor-neutral software can be used to analyze PET studies in neurology, cardiology, and oncology in preclinical and human molecular imaging research settings. The company's focus is on molecular quantification and pharmacokinetic modeling. Based in Zurich, PMOD Technologies was founded in 2003 as a spin-off from University Hospital Zurich and has a development team in Warsaw, Poland.
With the acquisition, Bruker expands its portfolio to now include ParaVision 360 and PMOD for MRI and nuclear molecular imaging translational research.
Copyright © 2019 AuntMinnieEurope.com